Entera Bio (NASDAQ:ENTX) Shares Up 1.1% – Time to Buy?

Entera Bio Ltd. (NASDAQ:ENTX) shares were up 1.1% during trading on Monday . The stock traded as high as $2.75 and last traded at $2.72. Approximately 176,489 shares were traded during trading, a decline of 84% from the average daily volume of 1,127,563 shares. The stock had previously closed at $2.69.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Entera Bio in a report on Monday, November 11th.

Entera Bio Stock Up 1.1 %

The business has a 50-day simple moving average of $1.93 and a two-hundred day simple moving average of $1.84. The company has a market cap of $97.34 million, a price-to-earnings ratio of -10.46 and a beta of 1.49.

Institutional Trading of Entera Bio

A hedge fund recently raised its stake in Entera Bio stock. Parkman Healthcare Partners LLC increased its holdings in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 2.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 411,076 shares of the company’s stock after purchasing an additional 9,558 shares during the period. Parkman Healthcare Partners LLC owned approximately 1.15% of Entera Bio worth $781,000 at the end of the most recent reporting period. 14.11% of the stock is currently owned by institutional investors.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.